Harnessing free energy calculations for kinome-wide selectivity in drug discovery campaigns with a Wee1 case study

  • Nat Commun. 2025 Aug 26;16(1):7962. doi: 10.1038/s41467-025-62722-w.
Jennifer Lynn Knight  1 Anthony J Clark  2 Jiashi Wang  2 Andrew Placzek  3 Pieter H Bos  2 Sathesh Bhat  2 Jeffrey A Bell  2 Sarah Silvergleid  2 Wu Yin  2 Felicia Gray  3 Shaoxian Sun  2 Karen Akinsanya  2 Robert Abel  2 Aleksey I Gerasyuto  4
Affiliations
  • 1. Schrödinger, Inc., New York, NY, USA. [email protected].
  • 2. Schrödinger, Inc., New York, NY, USA.
  • 3. Schrödinger, Inc., Portland, OR, USA.
  • 4. Schrödinger, Inc., New York, NY, USA. [email protected].
Abstract

Optimizing both on-target and off-target potencies is essential for developing effective and selective small-molecule therapeutics. Free energy calculations offer rapid potency predictions, usually within hours and with experimental accuracy and thus enables efficient identification of promising compounds for synthesis, accelerating early-stage drug discovery campaigns. While free energy predictions are routinely applied to individual proteins, here, we present a free energy framework for efficiently achieving kinome-wide selectivity that led to the discovery of selective Wee1 kinase inhibitors. Ligand-based relative binding free energy calculations rapidly identified multiple novel potent chemical scaffolds. Subsequent protein residue mutation free energy calculations that modified the Wee1 gatekeeper residue, significantly reduced their off-target liabilities across the kinome. Thus, with judicious use of this gatekeeper residue selectivity handle, applying this computational strategy streamlined the optimization of both on-target and off-target potencies, offering a roadmap to expedite drug discovery timelines by decreasing unanticipated off-target toxicities.

Products